Scancell (LON:SCLP) Hits New 52-Week High - What's Next?

Key Points

• New 52-week high: Scancell shares traded as high as GBX 14 and last at GBX 13.50 on heavy volume (~3.98M shares), with the 50-day and 200-day moving averages at GBX 12.49 and GBX 11.16 respectively.
• Financials show the company is still unprofitable—quarterly EPS of GBX (0.55), a negative net margin of 116.98%, PE of -24.55 and analysts forecast about -2.54 EPS for the current fiscal year; market cap is £140.1M.
• Business update: Scancell is a clinical-stage biotech using Immunobody® and Moditope® platforms, and its lead candidate iSCIB1+ has shown monotherapy activity and added benefit with checkpoint inhibitors in the ongoing Phase 2 SCOPE trial for melanoma.

Scancell Holdings plc (LON:SCLP - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as GBX 14 and last traded at GBX 13.50, with a volume of 3979924 shares traded. The stock had previously closed at GBX 12.50.

Scancell Stock Performance

The stock has a market cap of £140.10 million, a PE ratio of -24.55 and a beta of 0.33. The company has a debt-to-equity ratio of -193.29, a current ratio of 0.56 and a quick ratio of 13.01. The business has a 50 day moving average price of GBX 12.49 and a two-hundred day moving average price of GBX 11.16.

Scancell (LON:SCLP - Get Free Report) last released its quarterly earnings data on Thursday, January 29th. The company reported GBX (0.55) earnings per share for the quarter. Scancell had a negative net margin of 116.98% and a positive return on equity of 90.29%. As a group, equities research analysts forecast that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.

About Scancell

Scancell LSE: SCLP is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.